{"id":53396,"date":"2025-09-21T00:08:17","date_gmt":"2025-09-21T04:08:17","guid":{"rendered":"https:\/\/stockmarketwatch.com\/stock-market-news\/johnson-johnsons-myeloma-breakthrough-and-homan-bribery-allegations-surface\/53396\/"},"modified":"2025-09-21T00:08:17","modified_gmt":"2025-09-21T04:08:17","slug":"johnson-johnsons-myeloma-breakthrough-and-homan-bribery-allegations-surface","status":"publish","type":"post","link":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/johnson-johnsons-myeloma-breakthrough-and-homan-bribery-allegations-surface\/53396\/","title":{"rendered":"Johnson &#038; Johnson&#8217;s Myeloma Breakthrough and Homan Bribery Allegations Surface"},"content":{"rendered":"<h2>Key Takeaways<\/h2>\n<ul>\n<li><strong>Johnson &amp; Johnson (<a href=\"\/stock\/JNJ\">JNJ<\/a>) announced a 100% overall response rate (ORR) for its combination therapy of Tecvayli and Darzalex in newly diagnosed multiple myeloma patients, marking a significant advancement in cancer treatment.<\/strong><\/li>\n<li><strong>The promising results from the Phase 1\/2 study suggest a potential new frontline treatment option for multiple myeloma, a difficult-to-treat blood cancer.<\/strong><\/li>\n<li><strong>Separately, a report from MSNBC alleges that former high-ranking official Homan sought a $50,000 payment from individuals believed to be FBI agents posing as business executives.<\/strong><\/li>\n<\/ul>\n<p>Johnson &amp; Johnson (<a href=\"\/stock\/JNJ\">JNJ<\/a>) has reported groundbreaking clinical trial results for its combination therapy of <strong>Tecvayli<\/strong> (teclistamab) and <strong>Darzalex<\/strong> (daratumumab) in newly diagnosed multiple myeloma patients. The Phase 1\/2 study revealed a remarkable <strong>100% overall response rate (ORR)<\/strong>, indicating that all patients in the trial responded to the treatment. This significant development could redefine the standard of care for individuals battling this challenging blood cancer.<\/p>\n<p>The combination therapy leverages <strong>Tecvayli<\/strong>, a bispecific antibody targeting BCMA and CD3, and <strong>Darzalex<\/strong>, a CD38-directed monoclonal antibody, both key players in Johnson &amp; Johnson&#39;s oncology portfolio. <em>These findings underscore the company&#39;s commitment to advancing innovative treatments for difficult-to-treat cancers and could lead to substantial market opportunities in the oncology space.<\/em><\/p>\n<p>In unrelated news, a report from MSNBC has surfaced detailing allegations against Homan. The report claims Homan allegedly sought a payment of <strong>$50,000<\/strong> from individuals who were, in fact, FBI agents operating undercover as business executives. <em>This development could lead to further investigations and potential legal ramifications, drawing scrutiny to the individual involved.<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Key Takeaways Johnson &amp; Johnson (JNJ) announced a 100% overall response rate (ORR) for its combination therapy of Tecvayli and [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":50383,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"rank_math_schema_Article":[],"rank_math_focus_keyword":[],"rank_math_description":[],"financial_data_references":[],"stock_symbols_mentioned":[],"footnotes":""},"categories":[5012],"tags":[11180,376,5227,5251,5365,5383,5775,11177,11178,11179],"class_list":["post-53396","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-breaking-news","tag-orr","tag-jnj","tag-healthcare","tag-government","tag-legal","tag-biotech","tag-pharmaceuticals","tag-multiple-myeloma","tag-tecvayli","tag-darzalex"],"_links":{"self":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/53396","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/comments?post=53396"}],"version-history":[{"count":0,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/posts\/53396\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media\/50383"}],"wp:attachment":[{"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/media?parent=53396"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/categories?post=53396"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www2.stockmarketwatch.com\/stock-market-news\/wp-json\/wp\/v2\/tags?post=53396"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}